Monte Rosa Q1 net loss $44.5M; cash $671M; multiple pipeline advances

Monte Rosa Therapeutics, Inc.

Net loss of $44.5M vs net income of $46.9M in Q1 2025; collaboration revenue fell to $4.2M from $84.9M.
Cash, equivalents, and securities total $671.2M as of March 31, 2026, sufficient into 2029; $345M public offering closed in Jan.
MRT-8102 (NEK7 MGD) showed 85% CRP reduction in elevated CVD risk; Phase 2 studies in ASCVD, gout, and hidradenitis suppurativa planned H2 2026–H1 2027.
MRT-2359 (GSPT1 MGD): Phase 2 in mCRPC with AR mutations anticipated Q3 2026 after positive interim data; supply deal with Johnson & Johnson.
Novartis to initiate multiple Phase 2 studies of MRT-6160 (VAV1 MGD) in immune-mediated diseases in 2026; Monte Rosa eligible for up to $2.1B milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monte Rosa Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Monte Rosa Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-210298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.